Take a look around.
JIVI® (antihemophilic factor [recombinant] PEGylated-aucl) Pharmacokinetic Profile Compared to Eloctate® Showed Improved Characteristics in PK Study of Extended Half-life Recombinant FVIII Therapies
A head-to-head study directly comparing the pharmacokinetic (PK) profiles of two extended half-life (EHL) recombinant factor VIII (FVIII) therapies demonstrated improved PK characteristics for...Learn more
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
Bayer AG and BlueRock Therapeutics today announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on...Learn more
Explore Our Divisions
In line with our mission “Bayer: Science for A Better Life,” we aim to improve people’s quality of life.